4D Molecular Therapeutics Management
Management criteria checks 2/4
4D Molecular Therapeutics' CEO is David Kirn, appointed in Sep 2013, has a tenure of 10.67 years. total yearly compensation is $10.29M, comprised of 5.8% salary and 94.2% bonuses, including company stock and options. directly owns 2.59% of the company’s shares, worth $34.89M. The average tenure of the management team and the board of directors is 2.7 years and 3.5 years respectively.
Key information
David Kirn
Chief executive officer
US$10.3m
Total compensation
| CEO salary percentage | 5.8% |
| CEO tenure | 10.7yrs |
| CEO ownership | 2.6% |
| Management average tenure | 2.7yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
Jun 284D Molecular inks collaboration deal on machine learning technology
May 04We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
May 04Have Insiders Been Buying 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares?
Mar 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$10m | US$597k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$3m | US$586k | -US$107m |
| Sep 30 2022 | n/a | n/a | -US$105m |
| Jun 30 2022 | n/a | n/a | -US$102m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$5m | US$570k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$702k | US$451k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$554k | US$430k | -US$49m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$15m |
| Dec 31 2018 | US$546k | US$396k | -US$10m |
Compensation vs Market: David's total compensation ($USD10.29M) is above average for companies of similar size in the US market ($USD5.67M).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Kirn (60 yo)
10.7yrs
Tenure
US$10,286,808
Compensation
Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | US$581.44k | 0.20% $ 2.6m | |
| Co-Founder | 10.7yrs | US$10.29m | 2.59% $ 34.9m | |
| President & COO | 4.3yrs | US$4.54m | 0.012% $ 156.8k | |
| Chief Scientific Officer | less than a year | US$488.91k | no data | |
| Chief Medical Officer | 1.6yrs | US$3.96m | 0.0020% $ 27.5k | |
| Co-Founder & Chief of Staff | 11.3yrs | US$2.70m | no data | |
| Chief Financial & Business Officer | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2.7yrs | no data | 0.0034% $ 45.9k | |
| Chief Development Officer | 2.5yrs | no data | no data | |
| Senior VP & Therapeutic Area Head of Pulmonology | no data | no data | no data | |
| Controller | 7.8yrs | no data | no data |
2.7yrs
Average Tenure
60yo
Average Age
Experienced Management: FDMT's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | US$581.44k | 0.20% $ 2.6m | |
| Co-Founder | 10.7yrs | US$10.29m | 2.59% $ 34.9m | |
| Independent Director | 8.4yrs | US$239.83k | 0.063% $ 853.4k | |
| Independent Director | 3.8yrs | US$239.83k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 5.2yrs | US$352.62k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$345.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 3.5yrs | US$340.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
3.5yrs
Average Tenure
61yo
Average Age
Experienced Board: FDMT's board of directors are considered experienced (3.5 years average tenure).